Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy ...

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

H.C. Wainwright has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Sell rating, as announced on November 25, 2024, according to Finviz. Earlier, on November 7, 2024, Cantor Fitzgerald had ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.